Cardiol Therapeutics Inc (CRDL)

Feb 04, 2025

Cardiol Therapeutics to Present at Healthcare Conference, Highlighting Advances in Heart Disease Therapies - TipRanks

Feb 04, 2025

Feb 04, 2025

Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Newsfile

Feb 04, 2025

Feb 04, 2025

Heart Disease Breakthrough: Cardiol Therapeutics Unveils Latest Research at Major Healthcare Summit - StockTitan

Feb 04, 2025

Feb 04, 2025

Cardiol Therapeutics to present at Oppenheimer Healthcare Conference - Proactive Investors USA

Feb 04, 2025

Feb 03, 2025

Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol - Yahoo Finance

Feb 03, 2025

Feb 02, 2025

Cardiol Therapeutics (NASDAQ:CRDL) Rating Increased to Strong-Buy at RODMAN&RENSHAW - MarketBeat

Feb 02, 2025

Feb 01, 2025

Analysts Set Cardiol Therapeutics Inc. (NASDAQ:CRDL) PT at $8.40 - MarketBeat

Feb 01, 2025

Feb 01, 2025

Reviewing Cardiol Therapeutics (NASDAQ:CRDL) and CG Oncology (NASDAQ:CGON) - Defense World

Feb 01, 2025

Jan 31, 2025

Cardiol Therapeutics (NASDAQ:CRDL) Coverage Initiated by Analysts at Rodman & Renshaw - MarketBeat

Jan 31, 2025

Jan 31, 2025

Brokerages Set Cardiol Therapeutics Inc. (NASDAQ:CRDL) Price Target at $8.40 - Defense World

Jan 31, 2025

Jan 30, 2025

Rodman & Renshaw Begins Coverage on Cardiol Therapeutics (NASDAQ:CRDL) - Defense World

Jan 30, 2025

Jan 30, 2025

Cardiol Therapeutics (NASDAQ:CRDL) Raised to Strong-Buy at RODMAN&RENSHAW - Defense World

Jan 30, 2025

Jan 28, 2025

Rodman & Renshaw sets $7 target on Cardiol Therapeutics stock - MSN

Jan 28, 2025

Jan 28, 2025

Rodman & Renshaw sets $7 target on Cardiol Therapeutics stock By Investing.com - Investing.com Canada

Jan 28, 2025

Jan 17, 2025

Cardiol Therapeutics (TSE:CRDL) Trading Down 3.4%What's Next? - MarketBeat

Jan 17, 2025

Jan 17, 2025

Jane Street Group LLC Takes $29,000 Position in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World

Jan 17, 2025

Jan 17, 2025

Cardiol Therapeutics (TSE:CRDL) Shares Down 3.4% – Here’s What Happened - Defense World

Jan 17, 2025

Jan 15, 2025

Pericarditis Drugs Market reached US$ 544.4 million in 2023 - openPR

Jan 15, 2025

Jan 15, 2025

Critical Comparison: Black Diamond Therapeutics (NASDAQ:BDTX) & Cardiol Therapeutics (NASDAQ:CRDL) - Defense World

Jan 15, 2025

Jan 14, 2025

Top 4 Canadian Biotech Stocks (Updated January 2025) - Investing News Network

Jan 14, 2025

Jan 01, 2025

Cardiol Therapeutics Inc. (NASDAQ:CRDL) Short Interest Up 12.4% in December - MarketBeat

Jan 01, 2025

Dec 31, 2024

Appendix 3Y x4 - Investing News Network

Dec 31, 2024

Dec 27, 2024

Cardiol Therapeutics Sees Insider Buying From Leadership Team And Board Members - The Deep Dive

Dec 27, 2024

Dec 26, 2024

Guillermo Torre Purchases 17,240 Shares of Cardiol Therapeutics Inc. (TSE:CRDL) Stock - MarketBeat

Dec 26, 2024

Dec 24, 2024

Insider Buying: Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Buys 18,900 Shares of Stock - MarketBeat

Dec 24, 2024

Dec 24, 2024

2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases - Proactive Investors Australia

Dec 24, 2024

Dec 23, 2024

2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases | NASDAQ:CADL - Proactive Investors UK

Dec 23, 2024

Dec 21, 2024

HC Wainwright Has Positive Forecast for CRDL FY2024 Earnings - Defense World

Dec 21, 2024

Dec 20, 2024

FY2024 Earnings Forecast for CRDL Issued By HC Wainwright - MarketBeat

Dec 20, 2024

Dec 19, 2024

RAD 202 receives approval to start Phase 1 therapeutic trial - Investing News Network

Dec 19, 2024

Dec 19, 2024

PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis - The Manila Times

Dec 19, 2024

Dec 19, 2024

PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis - Investing News Network

Dec 19, 2024

Dec 19, 2024

PRISM MarketView Features Q&A with President and CEO David - GlobeNewswire

Dec 19, 2024

Dec 18, 2024

HC Wainwright Reiterates Buy Rating for Cardiol Therapeutics (NASDAQ:CRDL) - MarketBeat

Dec 18, 2024

Dec 17, 2024

Cardiex Completes Placement Ahead of CONNEQT US Launch - Investing News Network

Dec 17, 2024

Dec 17, 2024

BPH Global receives funding commitment of A$100,000 - Investing News Network

Dec 17, 2024

Dec 17, 2024

Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Bernard Lim Acquires 10,000 Shares of Stock - MarketBeat

Dec 17, 2024

Dec 17, 2024

David Elsley Buys 40,000 Shares of Cardiol Therapeutics Inc. (TSE:CRDL) Stock - MarketBeat

Dec 17, 2024

Dec 14, 2024

Cardiol Therapeutics (TSE:CRDL) Trading Down 2.1%What's Next? - MarketBeat

Dec 14, 2024

Dec 14, 2024

Cardiol Therapeutics (TSE:CRDL) Trading Down 2.1% – Here’s What Happened - Defense World

Dec 14, 2024

Dec 09, 2024

Townsquare Capital LLC Buys New Shares in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World

Dec 09, 2024

Dec 05, 2024

Cardiol Therapeutics (STU:CT9) Momentum Rank : 6 (As of Dec. 05, 2024) - GuruFocus.com

Dec 05, 2024

Dec 04, 2024

Cardiol Therapeutics (OTCMKTS:CRTPF) Shares Down 3.1% – Should You Sell? - Defense World

Dec 04, 2024

Dec 02, 2024

Cardiol Therapeutics (TSX:CRDL) Price-to-Operating-Cash-Flo - GuruFocus.com

Dec 02, 2024

Dec 01, 2024

CRDL (Cardiol Therapeutics) 50-Day SMA : $1.88 (As of Dec. 01, 2024) - GuruFocus.com

Dec 01, 2024

Dec 01, 2024

Cardiol Therapeutics (TSX:CRDL) Enterprise Value : C$168.30 Mil (As of Dec. 01, 2024) - GuruFocus.com

Dec 01, 2024

Dec 01, 2024

Cardiol Therapeutics (FRA:CT9) Price-to-Free-Cash-Flow : N/A (As of Dec. 01, 2024) - GuruFocus.com

Dec 01, 2024

Nov 29, 2024

3 Penny Stocks Ready to Break Out in 2025 - MarketBeat

Nov 29, 2024

Nov 29, 2024

3 Penny Stocks Ready To Break Out In 2025 - Barchart

Nov 29, 2024

Nov 29, 2024

Cardiol Therapeutics (CRDL-Q) QuotePress Release - The Globe and Mail

Nov 29, 2024